Shen Ke, Yuan Shuang, Su Ning, Tang Furong, Rehim Shamsnur, Wang Han, Guo Huihui, Zhang Yu, Wu Yufeng, Wang Hongjing
Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Oncol Rep. 2025 Jun;53(6). doi: 10.3892/or.2025.8901. Epub 2025 Apr 17.
Platinum‑resistant ovarian cancer (PROC) is a significant clinical challenge due to the limited number of treatment options and poor outcomes. Moreover, cytotoxic drugs have an unsatisfactory therapeutic efficacy, high toxicity and side effects. An antibody‑drug conjugate (ADC) is a novel cancer therapeutic strategy that combines an antibody, a linker and a payload. ADCs precisely target the tumor cells by binding to the antigen on the surface of tumor cells, thus accurately delivering the cytotoxic drugs and minimizing systemic toxicity. The approval of mirvetuximab soravtansine by the US Food and Drug Administration for treating folate receptor alpha‑positive, platinum‑resistant epithelial ovarian cancer has promoted studies on the use of ADCs in ovarian cancer. A phase III clinical trial showed that mirvetuximab soravtansine achieved an objective remission rate of 42.3% in platinum‑resistant, FRα‑positive ovarian cancer, compared with 15.9% using chemotherapy, demonstrating its immense potential for ADC development. The present review summarizes the research progress on the use of ADCs in PROC as a monotherapy and combination therapy and considers the future development direction of ADCs in PROC.
铂耐药卵巢癌（PROC）是一项重大的临床挑战，原因在于治疗选择有限且预后不佳。此外，细胞毒性药物的治疗效果不尽人意，毒性和副作用较大。抗体药物偶联物（ADC）是一种新型癌症治疗策略，它将抗体、连接子和有效载荷结合在一起。ADC通过与肿瘤细胞表面的抗原结合，精确靶向肿瘤细胞，从而准确递送细胞毒性药物并将全身毒性降至最低。美国食品药品监督管理局批准mirvetuximab soravtansine用于治疗叶酸受体α阳性、铂耐药上皮性卵巢癌，这推动了ADC在卵巢癌治疗中的应用研究。一项III期临床试验表明，mirvetuximab soravtansine在铂耐药、FRα阳性卵巢癌中的客观缓解率达到42.3%，而化疗的这一比例为15.9%，证明了其在ADC研发方面的巨大潜力。本综述总结了ADC作为单药治疗和联合治疗在PROC中的研究进展，并探讨了ADC在PROC中的未来发展方向。
